Role of membrane proteins in bacterial resistance to antimicrobial peptides

0556539 - MBÚ 2023 RIV US eng J - Článek v odborném periodiku
Vimberg, Vladimír - Buriánková, Karolína - Mazumdar, Aninda - Branny, Pavel - Novotná, Gabriela
Role of membrane proteins in bacterial resistance to antimicrobial peptides.
Medicinal Research Reviews. Roč. 42, č. 3 (2022), s. 1023-1036. ISSN 0198-6325. E-ISSN 1098-1128
Grant CEP: GA MŠMT(CZ) ED1.1.00/02.0109; GA MŠMT(CZ) LTAUSA18112; GA ČR(CZ) GA19-03269S; GA MZd(CZ) NV15-28807A
Institucionální podpora: RVO:61388971
Klíčová slova: staphylococcus-aureus * in-vitro * teicoplanin resistance * telavancin activity * confers resistance * vancomycin * oritavancin * dalbavancin * vrasr * tcaa * antimicrobial peptides * gram-positive bacteria * lipoglycopeptide antibiotics * membrane proteins * resistance
Obor OECD: Microbiology
Impakt faktor: 13.3, rok: 2022
Způsob publikování: Omezený přístup
https://onlinelibrary.wiley.com/doi/10.1002/med.21869

Several natural antimicrobial peptides (AMPs), including the novel semisynthetic lipoglycopeptide antibiotics telavancin, dalbavancin, and oritavancin, have been approved for clinical use to address the growing problem of multiple antibiotic-resistant Gram-positive bacterial infections. Nevertheless, the efficacy of these antibiotics has already been compromised. The SARS-CoV-2 pandemic led to the increased clinical use of all antibiotics, further promoting the development of bacterial resistance. Therefore, it is critical to gain a deeper understanding of the role of resistance mechanisms to minimize the consequential risks of long-term antibiotic use and misuse. Here, we summarize for the first time the current knowledge of resistance mechanisms that have been shown to cause resistance to clinically used AMPs, with particular focus on membrane proteins that have been reported to interfere with the activity of AMPs by affecting the binding of AMPs to bacteria.
Trvalý link: http://hdl.handle.net/11104/0330719